Organogenesis Holdings Inc. (ORGO): Total Liabilities
$164.81M
As of 2025-12-31
$118.31M
As of 2026-06-30
-3.6%
3-year compound annual growth
+2.1%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $164.81M | +46.4% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $112.57M | -37.9% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $181.36M | -1.3% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $183.69M | n/a | 2024-02-29, Balance as of period end |
| 2022-03-31 | $194.74M | n/a | 2023-03-01, Balance as of period end |
| 2021-12-31 | $201.92M | +36.1% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $148.41M | -10.1% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $165.10M | +41.6% | 2021-03-16, Balance as of period end |
| 2018-12-31 | $116.64M | -25.8% | 2020-03-09, Balance as of period end |
| 2017-12-31 | $157.28M | n/m | 2019-03-18, Balance as of period end |
| 2016-12-31 | $11.33M | n/a | 2018-03-14, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $164.81M | +46.4% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $501.83M | -0.1% |
| Insmed Inc (INSM) | 2025-12-31 | $1.53B | -12.3% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $663.99M | -20.5% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $528.12M | +18.6% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $415.23M | +16.9% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $3.01B | +26.7% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $601.51M | +17.6% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $490.36M | -8.4% |
Compare ORGO, HCM, INSM, OPK side by side · Screen every company in Pharmaceutical Preparations ↗